Frankfurt - Delayed Quote EUR

Cosmo Pharmaceuticals N.V. (C43.F)

55.50

0.00

(0.00%)

As of 8:04:35 AM GMT+2. Market Open.

Cosmo Highlights Strategic AI and GI Innovation Agenda at Digestive Disease Week(R) 2025

Dublin, Ireland--(Newsfile Corp. - May 5, 2025) - Cosmo is attending this year’s Digestive Disease Week® (DDW), held in San Diego, California from May 3-6, where its leadership team is advancing a focused agenda of strategic meetings with key opinion leaders (KOLs), innovators, and potential partners in AI and gastrointestinal (GI) drug development. ...

Newsfile 10 days ago

CMOPF
Cosmo Announces EU MDR Certification for Endovision's Cerebro, expanding its real-time AI ecosystem

Dublin, Ireland--(Newsfile Corp. - May 2, 2025) - Cosmo is excited to announce that Endovision Limited, a leading innovator in endoscopic imaging solutions, has received EU MDR certification[1] for Cerebro, a Real-Time AI-powered guide for complete Esophagogastroduodenoscopy (EGD) procedures. As one of the first Computer-Assisted Quality (CAQ) tools for endoscopy, Cerebro marks a significant step forward in transforming ...

Newsfile 13 days ago

CMOPF
Cosmo Pharmaceuticals Confirms Financial Guidance Following CHMP Opinion on Winlevi(R)

Dublin, Ireland--(Newsfile Corp. - April 29, 2025) - Following the recent CHMP opinion regarding the marketing authorization application for Winlevi® (clascoterone cream 1%) in Europe, Cosmo Pharmaceuticals N.V. (SIX: COPN) confirms that its financial guidance for 2025 remains unchanged. While the company is disappointed by the opinion, it maintains strong ...

Newsfile 15 days ago

CMOPF
Cosmo Receives Negative CHMP Opinion on Winlevi(R) (clascoterone Cream 1%) in Europe and Will Appeal the Decision

Ad hoc announcement pursuant to Art. 53 LR Dublin, Ireland--(Newsfile Corp. - April 29, 2025) - Cosmo Pharmaceuticals N.V. (SIX: COPN) announces that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a negative opinion on the marketing authorization application (MAA) for Winlevi® ...

Newsfile 16 days ago

CMOPF
Cosmo Publishes Agenda of AGM 2025

Dublin, Ireland--(Newsfile Corp. - April 29, 2025) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo” or the “Company”) today announced the convening of its Annual General Meeting 2025 to be held on Friday 30 May 2025, at 12:00 CEST, at Strawinskyhuis, Prinses Amaliaplein 3, 1077 XS Amsterdam, the Netherlands. The agenda includes, inter alia, the following discussion ...

Newsfile 16 days ago

CMOPF
Cosmo Appoints Federico Sommariva as Chief Legal Counsel

Dublin, Ireland--(Newsfile Corp. - April 1, 2025) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) today announced the appointment of Federico Sommariva ad Chief Legal Counsel. Federico reports to the CEO and is member of the management team. Federico Sommariva has many years of legal and management experience in ...

Newsfile last month

CMOPF
Cosmo Pharmaceuticals publishes Annual Report 2024

Ad hoc announcement pursuant to Art. 53 LR Dublin, Ireland--(Newsfile Corp. - March 21, 2025) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) has published today its Annual Report for the fiscal year ending December 31, 2024. As already outlined in the unaudited 2024 Full-Year ...

Newsfile last month

CMOPF
Cosmo Pharmaceuticals NV (CMOPF) (FY 2024) Earnings Call Highlights: Record Revenues and ...

Cosmo Pharmaceuticals NV (CMOPF) celebrates a transformational year with record profits and FDA approvals, while navigating investor concerns and strategic hurdles.

GuruFocus.com 2 months ago

COPN.SW
Cosmo Pharmaceuticals Delivers Record 2024 Results - Completes Phase III Enrollment for Androgenetic Alopecia in Males - Proposes Increased Dividend of 2.05 per share - Reinforcing Shareholder Value and Growth Momentum into 2025

Ad hoc announcement pursuant to Art. 53 LR FY 2024 Revenue of €266.8 million (unaudited) reaching upper end of guidance FY 2024 Operating Profit (unaudited) of €148.9 million, ...

Newsfile 2 months ago

CMOPF
Cosmo to Host Investor Day on April 9, 2025

Dublin, Ireland--(Newsfile Corp. - February 12, 2025) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) is pleased to announce that it will host an Investor Day on Wednesday, April 9, 2025. The live event will be held at the Hotel “Park Hyatt” at ...

Newsfile 2 months ago

CMOPF
Cosmo Appoints Andrea Cherubini as Chief AI Officer to Drive AI Expansion Across Portfolio

Dublin, Ireland--(Newsfile Corp. - February 11, 2025) - Planet Friendly Technologies, Inc.Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) today announced the appointment of Andrea Cherubini as Chief AI Officer effective immediately. This important decision reflects Cosmo’s commitment to integrating Artificial Intelligence as a core strategic pillar in its future growth and innovation roadmap. Andrea will report to the CEO and will be member ...

Newsfile 3 months ago

CMOPF
Cosmo and Glenmark Announces UK MHRA Approval of Winlevi(R) for Treatment of Acne

Dublin, Ireland and Mumbai, India and London, United Kingdom--(Newsfile Corp. - February 10, 2025) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) and Glenmark Pharmaceuticals Limited (Glenmark), a global research-led pharmaceutical company, today announced that Glenmark had received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) to market Winlevi® in the United Kingdom. Winlevi® is ...

Newsfile 3 months ago

CMOPF
Invitation to Cosmo's Unaudited Full Year 2024 Financial Results Webcast on 6 March 2025

Dublin, Ireland--(Newsfile Corp. - January 28, 2025) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) announced today that it will publish its unaudited Full-Year 2024 results on Thursday, 6 March 2025 at 7:00 am CET. Live conference call and video webcast presentation: ...

Newsfile 3 months ago

CMOPF
Cosmo Pharmaceuticals Announces Strong Full Year 2024 Revenue and Cash and Provides Business and Pipeline Updates

Ad hoc announcement pursuant to Art. 53 LR Revenue Growth: Full-year 2024 revenue of €265.7 million (unaudited), marking a 186% increase compared to 2023. Financial Strength: Year-end cash ...

Newsfile 4 months ago

CMOPF
Cosmo Pharmaceuticals Appoints Chief Strategy Officer

Dublin, Ireland--(Newsfile Corp. - December 12, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) is pleased to announce the appointment of Dominika Spilarova as its Chief Strategy Officer, effective January 10, 2025. This newly created role within Cosmo’s leadership team highlights the company's focus on strategy-led growth and innovation. She will be reporting to the CEO. ...

Newsfile 4 months ago

CMOPF
Cosmo Shareholders Approved Board Proposal to Appoint New Independent Auditor at Today's EGM

Dublin, Ireland--(Newsfile Corp. - October 18, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) shareholders today approved the proposal by the Board of Directors to appoint Deloitte Accountants B.V. as new independent auditor of the Company for the financial year ending on 31 December 2024. Cosmo’s previous auditor ...

Newsfile 6 months ago

CMOPF
Cosmo Pharmaceuticals Appoints New Chief Financial Officer

Ad hoc announcement pursuant to Art. 53 LR Dublin, Ireland--(Newsfile Corp. - October 11, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) is delighted to announce the appointment of Svetlana Sigalova as its new Chief Financial Officer, effective November 11, 2024. Svetlana will succeed Niall Donnelly, who has ...

Newsfile 6 months ago

CMOPF
Cosmo Pharmaceuticals NV (CMOPF) (H1 2024) Earnings Call Highlights: Revenue Surge and ...

Cosmo Pharmaceuticals NV (CMOPF) reports a remarkable revenue increase and strengthens its position with strategic alliances and innovative advancements.

GuruFocus.com 7 months ago

COPN.SW

MDT
Cosmo Pharmaceuticals Enhances Management Team with Newly Appointed Head of Global Business Development

Dublin, Ireland--(Newsfile Corp. - September 23, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) is excited to announce the appointment of Ms. Egle Gedrimaite, as the new Head of Global Business Development, effective October 1, 2024. Egle Gedrimaite will report to Giovanni Di Napoli, CEO of Cosmo. With extensive experience in expanding global business operations and ...

Newsfile 7 months ago

CMOPF
Cosmo Pharmaceuticals Highlights Study Published in "The Lancet" Demonstrating the Efficacy of GI Genius(TM) in Colonoscopy Procedures

Dublin, Ireland--(Newsfile Corp. - September 2, 2024) - Cosmo Intelligent Medical Devices (Cosmo IMD), a division of Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”), the developer and manufacturer of the GI Genius™ intelligent endoscopy system, is pleased to announce the publication of a landmark study in “The Lancet”. This study, titled “Polyp detection with colonoscopy assisted by ...

Newsfile 8 months ago

CMOPF

Performance Overview

Return	C43.F	MSCI WORLD (^990100-USD-STRD)
YTD	-17.78%	+2.96%
1-Year	-20.16%	+11.46%
3-Year	+24.87%	+41.75%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Cosmo Pharmaceuticals N.V. (C43.F)

Cosmo Highlights Strategic AI and GI Innovation Agenda at Digestive Disease Week(R) 2025

Cosmo Announces EU MDR Certification for Endovision's Cerebro, expanding its real-time AI ecosystem

Cosmo Pharmaceuticals Confirms Financial Guidance Following CHMP Opinion on Winlevi(R)

Cosmo Receives Negative CHMP Opinion on Winlevi(R) (clascoterone Cream 1%) in Europe and Will Appeal the Decision

Cosmo Publishes Agenda of AGM 2025

Cosmo Appoints Federico Sommariva as Chief Legal Counsel

Cosmo Pharmaceuticals publishes Annual Report 2024

Cosmo Pharmaceuticals NV (CMOPF) (FY 2024) Earnings Call Highlights: Record Revenues and ...

Cosmo Pharmaceuticals Delivers Record 2024 Results - Completes Phase III Enrollment for Androgenetic Alopecia in Males - Proposes Increased Dividend of 2.05 per share - Reinforcing Shareholder Value and Growth Momentum into 2025

Cosmo to Host Investor Day on April 9, 2025

Cosmo Appoints Andrea Cherubini as Chief AI Officer to Drive AI Expansion Across Portfolio

Cosmo and Glenmark Announces UK MHRA Approval of Winlevi(R) for Treatment of Acne

Invitation to Cosmo's Unaudited Full Year 2024 Financial Results Webcast on 6 March 2025

Cosmo Pharmaceuticals Announces Strong Full Year 2024 Revenue and Cash and Provides Business and Pipeline Updates

Cosmo Pharmaceuticals Appoints Chief Strategy Officer

Cosmo Shareholders Approved Board Proposal to Appoint New Independent Auditor at Today's EGM

Cosmo Pharmaceuticals Appoints New Chief Financial Officer

Cosmo Pharmaceuticals NV (CMOPF) (H1 2024) Earnings Call Highlights: Revenue Surge and ...

Cosmo Pharmaceuticals Enhances Management Team with Newly Appointed Head of Global Business Development

Cosmo Pharmaceuticals Highlights Study Published in "The Lancet" Demonstrating the Efficacy of GI Genius(TM) in Colonoscopy Procedures

Performance Overview